Generic Name and Formulations:
Palifermin 6.25mg/vial; lyophilized pwd for IV inj after reconstitution; preservative-free; contains mannitol.
Indications for KEPIVANCE:
To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. As supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients.
Limitations Of use:
Not established in non-hematologic malignancies. Not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. Not for use with melphalan 200mg/m2 as conditioning regimen.
See full labeling. Give as IV bolus inj for 6 doses total. 60mcg/kg per day for 3 consecutive days before myelotoxic therapy (give 3rd dose 24–48hrs prior to beginning myelotoxic therapy); then 60mcg/kg per day for 3 consecutive days after myelotoxic therapy completion (give 1st dose on the day of hematopoietic stem cell infusion after the infusion is completed, and at least 7 days after the most recent palifermin dose).
Potential for stimulation of tumor growth. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Keratinocyte growth factor (recombinant).
If heparin is used to maintain IV line, rinse line with saline before and after palifermin use. Do not give palifermin before, during, or within 24hrs of myelotoxic chemotherapy.
Skin toxicities (rash, erythema, edema, pruritus), oral toxicities (dysesthesia, tongue discoloration, tongue thickening, alteration of taste), fever, pain, arthralgias, dysesthesia, elevated serum amylase (Grade 3/4).
Single-use vials—3, 6
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline